What Happened to Chronic Traumatic Encephalopathy (CTE)?
Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative disease caused by repeated head impacts, commonly affecting athletes in contact sports and military personnel. While definitive diagnosis remains post-mortem, significant advancements in 2026 are pushing towards reliable living diagnostic methods and the first clinical trials for potential treatments.
Quick Answer
Chronic Traumatic Encephalopathy (CTE) is a degenerative brain disease resulting from repetitive head trauma, leading to symptoms like mood changes, cognitive decline, and dementia. Historically, it could only be diagnosed after death through brain autopsy. However, as of 2026, groundbreaking research is underway, including promising PET imaging techniques, blood biomarker identification, and the initiation of the first cell therapy clinical trials, aiming to enable diagnosis in living individuals and develop effective treatments.
📊Key Facts
📅Complete Timeline14 events
First Descriptions of 'Punch-Drunk Syndrome'
The condition now known as CTE was first identified in boxers and termed 'punch-drunk syndrome' or 'dementia pugilistica,' recognizing a link between repetitive head trauma and neurological decline.
Dr. Bennet Omalu Discovers CTE in Mike Webster
Forensic neuropathologist Dr. Bennet Omalu identifies Chronic Traumatic Encephalopathy (CTE) during the autopsy of former NFL player Mike Webster, marking a pivotal moment in the modern understanding of the disease.
VA-BU-CLF Brain Bank Opens
The VA-BU-CLF Brain Bank, a collaboration between the Department of Veterans Affairs, Boston University, and the Concussion Legacy Foundation, formally opens as the first tissue repository dedicated to CTE research.
First Documented CTE Case in a Military Veteran
Dr. Bennet Omalu publishes the first documented case of CTE in a military veteran, a 27-year-old Iraq War veteran who died by suicide, expanding the understanding of CTE's affected populations.
NFL Reaches Tentative Concussion Settlement
The NFL reaches a tentative $765 million settlement with over 4,500 retired players who filed lawsuits alleging the league concealed the dangers of concussions and long-term brain injury.
NFL Concussion Settlement Receives Final Approval
A federal judge gives final approval to the NFL concussion settlement, which becomes an uncapped fund expected to cost the NFL nearly $1 billion over 65 years to compensate former players for brain injuries.
NFL Publicly Acknowledges Link to CTE
After years of denial, the National Football League publicly admits the existence of CTE and its connection to the sport of football.
NINDS Consensus Criteria for Traumatic Encephalopathy Syndrome (TES) Developed
An expert consensus develops criteria for Traumatic Encephalopathy Syndrome (TES), the proposed clinical syndrome for CTE in living individuals, aiming to guide clinical evaluation and research.
BU Study Links Advanced CTE as Distinct Cause of Dementia
A major study from the Boston University CTE Center, published in Alzheimer's & Dementia, provides the clearest evidence that advanced CTE is a distinct cause of dementia, quadrupling the odds of dementia in affected individuals.
Penn Medicine Study Questions TES Criteria Accuracy
Research from Penn Medicine, published in Nature Medicine, finds that most people meeting proposed TES criteria do not show hallmark CTE pathology at autopsy, raising concerns about misdiagnosis.
Novel PET Imaging Shows Promise for Living CTE Diagnosis
A pioneering PET imaging method using the radiotracer 18F-OXD-2314 demonstrates potential for accurately identifying CTE biomarkers in living patients, a breakthrough discussed at the Society of Nuclear Medicine and Molecular Imaging's 2026 Annual Meeting.
First Cell Therapy Trial for CTE Cleared by FDA
TriCelX, Inc. announces FDA authorization for a Phase 1/2 clinical trial of XytriX™, a cell therapy designed to target neuroinflammation and tau pathology in CTE, marking the first such treatment study.
Blood Biomarker Research Advances Living CTE Diagnosis
New, yet-to-be-peer-reviewed data suggests a path toward diagnosing CTE in living people through blood samples, specifically by detecting the eMTBR-tau243 signal, offering a potential validated biomarker.
New Study: 1-in-4 Ex-NFL Players Had CTE
A new study from Mass General Brigham, Boston University, and the Concussion & CTE Foundation finds that at least one in four former NFL players who died between 2016 and 2021 had CTE, with severe cases strongly linked to dementia.
Follow this story
Get an email when this timeline gets a major update.
🔍Deep Dive Analysis
Chronic Traumatic Encephalopathy (CTE) has a history dating back to the 1920s when it was first described in boxers as 'punch-drunk syndrome' or 'dementia pugilistica'. However, it gained widespread public and scientific attention in the early 2000s due to the pioneering work of forensic neuropathologist Dr. Bennet Omalu. In 2002, Omalu discovered and identified CTE in the brain of former NFL player Mike Webster, who had suffered years of neurological and behavioral issues. His findings, initially met with skepticism and resistance from the National Football League (NFL), highlighted a distinct tauopathy different from Alzheimer's disease, characterized by abnormal tau protein deposits in the brain.
The growing evidence of CTE in deceased athletes, particularly football players, led to increased public awareness and significant legal challenges. The Boston University CTE Center, established as part of the larger Alzheimer's Disease Research Center in 1996 and formally opening its VA-BU-CLF Brain Bank in 2008, became a leading institution for CTE research, collecting and studying post-mortem brains. In 2013, the NFL reached a tentative $765 million settlement with over 4,500 retired players who had sued the league over concussion-related brain injuries, which was finalized in 2015 as an uncapped fund expected to exceed $1 billion. The NFL publicly acknowledged the link between football and CTE in March 2016.
Despite significant progress in understanding CTE's neuropathology, a definitive diagnosis in living individuals has remained elusive, relying solely on post-mortem examination of brain tissue. This limitation has hampered clinical management and the development of targeted treatments. However, 2026 has seen a surge in promising research aimed at overcoming this diagnostic hurdle. In January 2026, Endeavor Health announced its participation in a trial to diagnose CTE in living patients using PET scans to detect tau and amyloid proteins. A major study from the Boston University CTE Center, published in January 2026, provided the clearest evidence to date, establishing that advanced CTE is a distinct cause of dementia, increasing the odds of dementia fourfold in affected individuals. This study also highlighted that CTE-related dementia is often misdiagnosed as Alzheimer's disease during life.
Further advancements in 2026 include a novel PET imaging method, 18F-OXD-2314, which showed potential in June 2026 for accurately identifying CTE biomarkers in living patients by detecting unique tau pathology. Research in July 2026 also explored blood biomarkers, specifically eMTBR-tau243, as a potential path towards a living diagnosis. On the treatment front, TriCelX, Inc. received FDA clearance in June 2026 for a Phase 1/2 clinical trial of XytriX™, the first cell therapy ever to be studied for CTE, targeting chronic neuroinflammation and tau pathology. These developments signify a critical turning point in the fight against CTE, moving from solely post-mortem understanding to active pursuit of in-life diagnosis and therapeutic interventions. However, a May 2026 Penn Medicine study cautioned that proposed clinical criteria for Traumatic Encephalopathy Syndrome (TES) often do not match actual CTE pathology at autopsy, raising concerns about potential misdiagnosis if widely adopted clinically without more reliable biomarkers.
As of August 25, 2026, a new study from Mass General Brigham, Boston University, and the Concussion & CTE Foundation reported that at least 1-in-4 former NFL players who died between 2016 and 2021 had CTE, with severe CTE strongly associated with dementia. This ongoing research underscores the continued prevalence and impact of CTE, while the scientific community actively seeks breakthroughs for diagnosis and treatment in living individuals.
What If...?
Explore alternate histories. What if Chronic Traumatic Encephalopathy (CTE) made different choices?